Lantern Pharma Inc.'s SEC filings document a clinical-stage oncology company built around AI-enabled drug development, its RADR platform and related research technologies. The filings include Form 8-K reports for financial results, Regulation FD presentations, and demonstrations of withZeta.ai, including platform capabilities, commercial architecture, rare-cancer research applications and revenue strategy disclosures.
Proxy and annual-meeting filings cover board elections, equity incentive plan matters, option repricing, independent auditor ratification and stockholder voting results. The filing record also includes exhibit-based press releases and presentations, Inline XBRL cover data, and forward-looking-statement risk language tied to Lantern Pharma's clinical programs, AI platforms, capital needs and development-stage biotechnology operations.